SYMBYX Biome

SYMBYX Biome operated in medical devices and therapeutics, focusing on photobiomodulation and low-level laser therapy for neurological symptoms, pain, inflammation and skin-related applications. Its product range included the PDCare Laser and SYMBYX Neuro Helmet, described for neurological use, as well as the DuoCare 904 Laser, PhysioCare Laser and DermaCare Laser. The company described its devices as medical-grade, non-invasive and portable, with products spanning home-use and professional contexts. Its current position is also materially affected by the stated cessation of commercial operations, which differentiates its present availability from an operating medical-device business and may limit new sales or ongoing service.

SYMBYX Biome was founded in December 2019 and recorded a seed round in 2020, followed by a Series A financing of A$3.3 million in May 2021, approximately US$2.56 million. That financing is the clearest identified growth inflection point, though the seed amount and detailed investor identities are unavailable. The company’s product portfolio covered several applications, from the PDCare Laser and SYMBYX Neuro Helmet for neurological symptoms to devices aimed at pain, inflammation and skin-related therapy. The available employee estimate places the organization in the 11–50 range, but does not provide a time series to show hiring or workforce growth. The most consequential current signal is that SYMBYX Biome has ceased commercial operations; warranty inquiries are directed to its listed email address.